Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74
These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
Pfizer is likely to show GSK significant competition
Subscribe To Our Newsletter & Stay Updated
